Niagen Bioscience (NAGE) Net Income towards Common Stockholders (2010 - 2026)

Niagen Bioscience (NAGE) has 16 years of Net Income towards Common Stockholders data on file, last reported at $6.3 million in Q1 2026.

• On a quarterly basis, Net Income towards Common Stockholders rose 24.79% year-over-year to $6.3 million in Q1 2026; TTM through Mar 2026 was $18.6 million, a 32.13% increase from a year earlier, with the FY2025 full-year figure at $17.4 million, up 103.3% from the prior year.
• Net Income towards Common Stockholders for Q1 2026 stood at $6.3 million, up from $4.1 million in the prior quarter.
• Over the last five years, Net Income towards Common Stockholders for NAGE reached as high as $7.2 million in Q4 2024 and fell as low as -$11.7 million in Q2 2022.
• Historically, Net Income towards Common Stockholders has averaged -$968352.9 across 5 years, with a median of -$270000.0 in 2023.
• On a YoY basis, Net Income towards Common Stockholders climbed as much as 24160.0% in 2025 and fell as far as 42.44% in 2025.
• Year by year, Net Income towards Common Stockholders stood at -$1.6 million in 2022, then jumped by 82.9% to -$270000.0 in 2023, then soared by 2758.89% to $7.2 million in 2024, then sank by 42.44% to $4.1 million in 2025, then soared by 52.9% to $6.3 million in 2026.
• Per Business Quant data, the three most recent Net Income towards Common Stockholders figures were $6.3 million in Q1 2026, $4.1 million in Q4 2025, and $4.6 million in Q3 2025.